Alzheimer's disease and Down's syndrome: Roles of APP, trophic factors and ACh

Trends in Neurosciences

Volumn 25, Issue 2, 2002, Pages 79-84

  Isacson, Ole ^a   Seo, Hyemyung ^a   Lin, Ling ^a   Albeck, David ^b   Granholm, Ann Charlotte ^c  

^a MCLEAN HOSPITAL   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; MONOCLONAL ANTIBODY; NERVE GROWTH FACTOR;

ALZHEIMER DISEASE; AMNESIA; BRAIN REGION; CELL LOSS; CELL MEMBRANE TRANSPORT; CHOLINERGIC NERVE CELL; DOWN SYNDROME; HIPPOCAMPUS; HUMAN; LONG TERM POTENTIATION; NERVE CELL; NERVE ENDING; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; REVIEW; SIGNAL TRANSDUCTION; SYNAPSE; TRANSGENIC MOUSE;

EID: 0036468772     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-2236(02)02037-4     Document Type: Review

References (77)

1. Abnormalities of the nucleus basalis in Down's syndrome
2. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome
3. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome
4. Reduction in trkA immunoreactive neurons is not associated with overexpression of galaninergic fibers within the nucleus basalis in Down's syndrome
5. Complement association with neurons and beta-amyloid deposition in the brains of aged individuals with Down syndrome
6. Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation
7. Cholinergic modulation of amyloid processing and dementia in animal models of Alzheimer's disease
8. Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice
9. Outcome measures in Alzheimer's disease: Do they go far enough?
10. A retrospective study of neuroradiological abnormalities detected on structural magnetic resonance imaging of the brain in elderly patients with cognitive impairment
11. Clues to early Alzheimer dementia in the outpatient setting
12. Alpha-synuclein-positive structures in cases with sporadic Alzheimer's disease: Morphology and its relationship to tau aggregation
13. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia
14. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease
15. Cholinergic markers in elderly patients with early signs of Alzheimer disease
16. NTR and TrkA in Alzheimer's disease
17. Down-regulation of trkA mRNA within nucleus basalis neurons in individuals with mild cognitive impairment and Alzheimer's disease
18. Physostigmine and recent memory: Effects in young and aged nonhuman primates
19. Cholinergic markers in Alzheimer disease
20. Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin 1 and amyloid presursor protein transgenes
21. NTR cholinergic basal forebrain septohippocampal pathway
22. Neuropeptides in hippocampus and cortex in transgenic mice overexpressing V717F beta-amyloid presursor protein-initial observation
23. Chronic cognitive decifits and amyloid precursor protein elevation after immunotoxin lesions of the basal forebrain cholinergic system
24. Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome
25. Alterations in APP and NGF levels in an animal model of Down's syndrome
26. Segmental trisomy of murine chromosome 16: A new model system for studying Down syndrome
27. Failed retrograde transport of NGF in a mouse model of Down's syndrome: Reversal of cholinergic neurodegenerative phenotypes following NGF infusion
28. Ts65Dn mice, a model for Down's syndrome, have deficits in context discrimination learning suggesting impaired hippocampal function
29. 2+ concentration, and neurotoxicity and increase antioxidant enzyme activities in hippocampal neurons
30. Systemic administration of a nerve growth factor conjugate reverses aged-related cognitive dysfunction and prevents cholinergic neuron atrophy
31. Carrier mediated delivery of NGF: Alterations in basal forebrain neurons in aged rats revealed using antibodies against low and high affinity NGF receptors
32. Degenerative changes in forebrain cholinergic nuclei correlate with cognitive impairments in aged rats
33. Levels of nerve growth factor and its mRNA in the central nervous system of the rat correlate with cholinergic innervation
34. Development and regional expression of beta nerve growth factor messenger RNA and protein in the rat central nervous system
35. Rat beta-nerve growth factor sequence and site of synthesis in the adult hippocampus
36. The localization of nerve growth factor-like immunoreactivity in the adult rat basal forebrain and hippocampal formation
37. In situ hybridization detection of trkA mRNA in brain: Distribution, colocalization with p75NGFR and up-regulation by nerve growth factor
38. Colocalization of choline acetyltransferase and nerve growth factor receptor in rat basal forebrain
39. Nerve growth factor mRNA-containing cells are distributed within regions of cholinergic neurons in the rat basal forebrain
40. p140trk mRNA marks NGF-responsive forebrain neurons: Evidence that trk gene expression is induced by NGF
41. Nerve growth factor signaling, neuroprotection, and neural repair
42. Characterization of nerve growth factor (NGF) release from hippocampal neurons: Evidence for a constitutive and an unconventional sodium-dependent regulated pathway
43. Intrastriatal and intraventricular infusion of brain-derived neurotrophic factor in the cynomologous monkey: Distribution, retrograde transport and co-localization with substantia nigra dopamine-containing neurons
44. Reduction in p140-TrkA receptor protein within the nucleus basalis and cortex in Alzheimer's disease
45. Neurotrophin receptors in Alzheimer's disease
46. Nerve growth factor in Alzheimer's disease: Increased levels throughout the brain coupled with declines in nucleus basalis
47. Nerve growth factor mRNA in peripheral and central rat tissues and in the human central nervous system: Lesion effects in the rat brain and levels in Alzheimer's disease
48. Nerve growth factor mRNA and protein levels measured in the same tissue from normal and Alzheimer's disease parietal cortex
49. Nerve growth factor in Alzheimer's disease: Defective retrograde transport to nucleus basalis
50. Normal beta-NGF content in Alzheimer's disease cerebral cortex and hippocampi
51. Detection of NGF-like activity in human brain tissue: Increased levels in Alzheimer's disease
52. Nerve growth factor (NGF) in cerebrospinal fluid (CSF) from patients with various neurological disorders
53. Cerebrospinal fluid levels of amyloid precurser protein and amyloid β-peptide in Alzheimer's disease and major depression-inverse correlation with dementia severity
54. Is cognitive status during aging dependent upon a reciprocal relationship between NGF in basal forebrain and hippocampus?
55. Atrophy of cholinergic basal forebrain neurons following excitotoxic cortical lesions is reversed by intravenous administration of an NGF conjugate
56. Nerve growth factor-induced neuronal differentiation is accompanied by differential induction and localization of the amyloid precursor protein (APP) in PC12 cells and variant PC12S cells
57. Nerve growth factor-induced neuronal differentiation is accompanied by differential splicing of beta-amyloid precursor mRNAs in the PC12 cell line
58. 1-40
59. Translating cell biology into therapeutic advances in Alzheimer's disease
60. Amyloid precursor protein potentiates the neurotrophic activity of NGF
61. Cholinergic control of nerve growth factor in adult rats: Evidence from cortical cholinergic deafferentation and chronic drug treatment
62. Role of the cholinergic system in the regulation of neurotrophin synthesis
63. Altered NGF protein levels in different brain areas after immunolesion
64. Beta-amyloid (1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology
65. Selective antibody-induced cholinergic cell and synapse loss produce sustained hippocampal and cortical hypometabolism with correlated cognitive deficits
66. Hippocampal plasticity induced by primed burst, but not long-term potentiation stimulation is impaired in area CA1 of aged Fischer 344 rats
67. Nerve growth factor release is facilitated by long term potentiation and primed burst potentiation inducing stimuli in the rat hippocampal slice
68. Acute application of NGF increases the firing rate of aged rat basal forebrain neurons
69. Activity-dependent release of endogenous brain-derived neurotrophic factor from primary sensory neurons detected by ELISA in situ
70. Cortico-hippocampal APP and NGF levels are dynamically altered by cholinergic muscarinic antagonist of M1 agonist treatment in normal mice
71. Estrogen and nerve growth factor - Neuroprotection and repair in Alzheimer's disease
72. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors
73. Protein phosphorylation inhibits production of Alzheimer amyloid β/A4 peptide
74. Activation of protein kinase C inhibits cellular production of the amyloid β-protein
75. Regulation by phorbol esters of amyloid precursor protein release from Swiss 3T3 fibroblasts overexpressing protein kinase Cα
76. Role of neurotransmission in the regulation of amyloid beta-protein precursor processing
77. Increased secretion of the amino-terminal fragment of amyloid precursor protein in brains of rats with a constitutive up-regulation of protein kinase C